Militia Capital Partners LP Has $2.16 Million Holdings in Medpace Holdings, Inc. $MEDP

Militia Capital Partners LP lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 62.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,200 shares of the company’s stock after selling 7,000 shares during the period. Medpace makes up approximately 1.0% of Militia Capital Partners LP’s investment portfolio, making the stock its 19th largest position. Militia Capital Partners LP’s holdings in Medpace were worth $2,159,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Norges Bank acquired a new stake in shares of Medpace during the second quarter worth $66,597,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the period. Clarkston Capital Partners LLC acquired a new position in shares of Medpace in the second quarter valued at about $40,569,000. Finally, Bares Capital Management Inc. grew its stake in shares of Medpace by 319.2% in the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after acquiring an additional 119,608 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MEDP. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a report on Friday, March 6th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Leerink Partners reduced their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research note on Friday, February 13th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $486.67.

Medpace Stock Up 0.7%

Shares of Medpace stock opened at $453.64 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The company has a market capitalization of $12.87 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.16 and a beta of 1.44. The firm’s 50-day moving average price is $520.96 and its two-hundred day moving average price is $539.27.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the company earned $3.67 EPS. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.